Allakos Inc. Stock News

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available on Seeking Alpha, iTunes, Stitcher and Spotify. U.S.

Allakos (NASDAQ:ALLK) had its target price decreased by The Goldman Sachs Group from $122.00 to $60.00 in a research report report published on Thursday morning, Analyst Ratings Network reports. The Goldman Sachs Group currently has a neutral rating on the stock. A number of other analysts have also commented on ALLK. Jefferies Financial Group lowered []

This Nasal Polyposis Drug market research stud offers proper industry viewpoint, market size, growth, future trends and trading. All this are taken into consideration while preparing the market report with the forecast period from 2021 to 2027. This report

Allakos (NASDAQ:ALLK) was downgraded by analysts at Cowen from an outperform rating to a market perform rating in a report released on Wednesday, Price Targets.com reports. Several other analysts have also recently issued reports on ALLK. Zacks Investment Research upgraded shares of Allakos from a sell rating to a hold rating in a research note []

Allakos Inc. (NASDAQ:ALLK) was the target of unusually large options trading activity on Wednesday. Stock investors purchased 15,170 call options on the company. This represents an increase of 2,689% compared to the average volume of 544 call options. In other Allakos news, Director Steven P. James sold 4,000 shares of the businesss stock in a [] The post Stock Traders Purchase High Volume of Allakos Call Options (NASDAQ:ALLK) appeared first on ETF Daily News .

Allakos Inc. (NASDAQ:ALLK) concluded the trading at $8.55 on Wednesday, December 22 with a fall of -89.87% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $84.39 and 5Y monthly beta was reading 0.88 with its price kept floating in the range At $8.55 Price, Allakos Inc. (ALLK) Is Sitting And Waiting Read More »

Allakos (NASDAQ:ALLK) was downgraded by research analysts at Lifesci Capital from an outperform rating to a market perform rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. Several other research firms have also recently weighed in on ALLK. Zacks Investment Research upgraded Allakos from a sell rating to a hold []

This article was originally published on TipRanks.com Allakos, Inc. The post Allakos Reveals Topline Results from ENIGMA 2 & KRYPTOS Studies; Shares Crash appeared first on Smarter Analyst .

SVB Leerink downgraded shares of Allakos (NASDAQ:ALLK) from an outperform rating to a market perform rating in a research report report published on Wednesday morning, PriceTargets.com reports. SVB Leerink currently has $17.00 price objective on the stock, down from their prior price objective of $150.00. A number of other research analysts have also weighed in [] The post Allakos (NASDAQ:ALLK) Lowered to Market Perform at SVB Leerink appeared first on ETF Daily News .

Allakos Inc. (NASDAQ:ALLK) shares hit a new 52-week low during trading on Wednesday after Bank of America downgraded the stock from a buy rating to an underperform rating. The company traded as low as $8.95 and last traded at $10.24, with a volume of 417020 shares changing hands. The stock had previously closed at $84.39. []

Allakos Inc (NASDAQ: ALLK) announced its results from Enigma II, Phase III placebo-controlled, double-blind clinical research of lirentelimab on people battling EG (eosinophilic gastritis) and went up by around 80%. The company also concluded its Kryptos study of lirentelimab on people with biopsy-confirmed EOE (eosinophilic esophagitis). Both the studies met all their co-primary endpoints. How does top [] The post Allakos Inc. down 80% after announcing topline phase III results from its Enigma II clinical study appeared first on Invezz .

Allakos Inc. (NASDAQ:ALLK) has a beta value of 0.75 and has seen 23.49 million shares traded in the recent trading session. The company, currently valued at $4.51B, closed the recent trade at $10.11 per share which meant it lost -$74.28 on the day or -88.02% during that session. The ALLK stock price is -1462.61% off Allakos Inc. Shares Are Down -41.40% Since The Beginning Of The Year Read More »